Tamsulosin Uses, Dosage, Side Effects & Warnings | DrugsAtlas
Authoritative Clinical Reference
Navigation
Therapeutic Class
Alpha-adrenergic antagonist
Subclass
Selective alpha-1A adrenergic receptor blocker
Speciality
Urology
Schedule (India)
Schedule H
Routes
Oral
Formulations
| Form | Strength |
|---|---|
| Modified-release capsules/tablets | 0.4 mg |
| Capsules (limited availability) | Unidentified |
Adult indications
INDICATIONS + DOSING — FOR CLINICIAN USE ONLY
Primary Indications (Approved / Standard in India)
1. Benign Prostatic Hyperplasia (BPH) — Lower Urinary Tract Symptoms (LUTS)
| Parameter | Details |
|---|---|
| Starting dose | 0.4 mg orally once daily, taken 30 minutes after the same meal each day |
| Titration | Not routinely required; may increase to 0.8 mg once daily after 2–4 weeks if response inadequate and drug well tolerated |
| Usual maintenance dose | 0.4 mg once daily |
| Maximum dose | 0.8 mg once daily |
Clinical Notes:
- Do not crush, chew, or open modified-release capsules
- Response typically observed within 1–2 weeks of initiation
- Evaluate for orthostatic hypotension risk at initiation, particularly in elderly
- Not effective for prostatic obstruction requiring surgical intervention
Secondary Indications — Adults (Off-label, if any)
| Indication | Dose | Duration | Notes |
|---|---|---|---|
| Distal ureteric stones — Medical Expulsion Therapy (MET) — OFF-LABEL | 0.4 mg once daily | Up to 4–6 weeks or until stone passage | Specialist only (Urology). Most effective for stones 5–10 mm in distal ureter. Evidence: Multiple meta-analyses support efficacy; standard practice in Indian urology. |
| Chronic prostatitis / Chronic pelvic pain syndrome (CP/CPPS) — OFF-LABEL | 0.4 mg once daily | 6–12 weeks trial | Specialist only. Evidence: Limited RCT data; used in Indian urological practice for symptom relief. |
Paediatric indications
PAEDIATRIC DOSING (Specialist Only)
Primary Indications (Approved / Standard in India)
Not applicable — Tamsulosin is not approved for routine paediatric use in India.
Secondary Indications — Paediatrics (Off-label, if any)
| Indication | Age | Dose | Duration | Notes |
|---|---|---|---|---|
| Posterior urethral valve (PUV) — residual bladder outlet obstruction — OFF-LABEL | ≥2 years | 0.2 mg once daily | As directed by specialist | Specialist only (Paediatric urology/nephrology). Adjust based on weight and clinical response. Evidence: Limited case series; select Indian tertiary centre practice. |
| Neurogenic bladder / Dysfunctional voiding — OFF-LABEL | ≥2 years | 0.2 mg once daily | As directed by specialist | Specialist only. Monitor closely for hypotension and dizziness. Evidence: Limited; based on specialist practice. |
Not recommended below 2 years of age except under close paediatric urology or nephrology supervision.
Safety Monitoring:
- Baseline and periodic blood pressure (supine and standing)
- Monitor for dizziness, syncope, excessive fatigue
- Assess clinical response and voiding parameters
Renal Adjustments
| Renal Function | Recommendation |
|---|---|
| Mild to moderate impairment (CrCl ≥30 mL/min) | No dose adjustment required |
| Severe impairment (CrCl <30 mL/min) | Use with caution; limited pharmacokinetic data |
| CrCl <10 mL/min | Avoid 0.8 mg dose; use standard 0.4 mg with close monitoring |
| Haemodialysis | No specific data; not significantly dialysed; use with caution |
Hepatic adjustment
Contraindications
- Known hypersensitivity to tamsulosin hydrochloride or any excipient
- History of symptomatic orthostatic hypotension
- Severe hepatic impairment (Child-Pugh C)
- Concurrent use with potent CYP3A4 inhibitors (ketoconazole, itraconazole) in patients who are CYP2D6 poor metabolizers
Cautions
- Elderly patients — increased susceptibility to orthostatic hypotension and falls
- Volume depletion or concurrent diuretic therapy
- Intraoperative Floppy Iris Syndrome (IFIS) — may complicate cataract surgery; document drug history and inform ophthalmologist
- Patients on antihypertensive medications — additive hypotensive effects
- Priapism — rare but requires immediate attention
- Severe renal impairment (CrCl <10 mL/min) — limited data
- Patients with planned ophthalmic surgery — assess timing of drug discontinuation
Pregnancy
| Parameter | Details |
|---|---|
| Applicability | Not applicable — drug indicated only for males |
| Safety in pregnancy | Not studied; no obstetric indication |
| Preferred alternatives | Not applicable |
| Monitoring | Not applicable |
Lactation
| Parameter | Details |
|---|---|
| Applicability | Not applicable — drug indicated only for males |
| Compatibility with breastfeeding | Not applicable |
| Milk levels | No data available |
| Infant monitoring | Not applicable |
Elderly'
| Parameter | Recommendation |
|---|---|
| Starting dose | 0.4 mg once daily |
| Titration | Slower titration if escalating to 0.8 mg; reassess tolerance after 4 weeks |
| Extra risks | Higher susceptibility to orthostatic hypotension, dizziness, syncope, and falls. Advise slow positional changes. Maintain adequate hydration. Consider fall risk assessment in frail elderly. |
Major drug interactions
| Interacting Drug | Mechanism / Effect | Recommendation |
|---|---|---|
| Strong CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir, clarithromycin) | Marked increase in tamsulosin plasma concentration | Avoid concurrent use; if unavoidable, close monitoring and consider dose reduction |
| Strong CYP2D6 inhibitors (paroxetine, fluoxetine, bupropion) | Increased tamsulosin exposure (~30%) | Use with caution; monitor for hypotensive symptoms |
| PDE-5 inhibitors (sildenafil, tadalafil, vardenafil) | Additive hypotensive effect | Space doses by at least 4–6 hours; monitor blood pressure; counsel patient |
| Other alpha-1 blockers (prazosin, doxazosin, terazosin, alfuzosin) | Synergistic hypotension | Avoid concurrent use |
Moderate drug interactions
| Interacting Drug | Effect | Recommendation |
|---|---|---|
| Antihypertensives (ACE inhibitors, ARBs, beta-blockers, CCBs, diuretics) | Additive blood pressure lowering | Monitor BP; adjust antihypertensive doses if symptomatic hypotension occurs |
| Cimetidine | Modest increase in tamsulosin levels (~26%) | Clinical monitoring; routine dose adjustment usually not required |
| Warfarin | Isolated case reports of altered INR | Monitor INR if initiating or stopping tamsulosin; no routine adjustment |
| Furosemide / Thiazides | Volume depletion may worsen orthostatic hypotension | Ensure adequate hydration; monitor postural symptoms |
| NSAIDs | May reduce efficacy of antihypertensive effect; potential for worsening postural symptoms in some patients | Monitor clinical response |
Common Adverse effects
- Dizziness
- Abnormal ejaculation (retrograde ejaculation, reduced ejaculate volume)
- Headache
- Rhinitis / nasal congestion
- Asthenia / fatigue
- Orthostatic hypotension (less common than non-selective alpha-blockers)
Serious Adverse effects
| Adverse Effect | Clinical Notes |
|---|---|
| Severe hypotension / syncope | Requires immediate discontinuation; evaluate for contributing factors (dehydration, concurrent medications) |
| Intraoperative Floppy Iris Syndrome (IFIS) | Risk persists even after drug discontinuation; inform ophthalmologist prior to cataract surgery |
| Priapism | Rare; requires urgent discontinuation and immediate urological referral |
| Angioedema / severe hypersensitivity | Rare; discontinue immediately and manage appropriately |
Monitoring requirements
Baseline:
- Blood pressure (supine and standing)
- IPSS (International Prostate Symptom Score) for objective symptom assessment
- Renal and hepatic function if clinically indicated
- Document any planned ophthalmic surgery
After initiation/dose change:
- Monitor for orthostatic symptoms (dizziness, light-headedness) during first 1–2 weeks
- Blood pressure check if on concurrent antihypertensives
- Assess symptom improvement (IPSS, uroflowmetry if available) at 4–6 weeks
Long-term:
- Periodic IPSS reassessment every 6–12 months
- Blood pressure monitoring during routine follow-up
- Document tamsulosin use prominently if ophthalmic surgery planned
Brands in India
| Brand Name | Manufacturer |
|---|---|
| Urimax | Cipla |
| Contiflo | Sun Pharma |
| Veltam | Aristo |
| Flotral | Intas |
| Tamlocept | Lupin |
| Dynapres | Micro Labs |
Common Fixed-Dose Combinations (FDCs):
- Tamsulosin 0.4 mg + Dutasteride 0.5 mg (e.g., Urimax D, Veltam Plus, Dutas T)
- Tamsulosin 0.4 mg + Finasteride 5 mg
Price range (INR)
| Formulation | Approximate Price |
|---|---|
| Tamsulosin 0.4 mg MR capsule (per unit) | ₹7–20 |
| Tamsulosin + Dutasteride FDC (per capsule) | ₹10–25 |
Regulatory status: Tamsulosin is included in NLEM 2022; pricing under NPPA control for scheduled formulations.
Clinical pearls
- Timing consistency is important — Administer after the same meal each day to reduce pharmacokinetic variability and minimise hypotension risk.
- IFIS alert is mandatory — Always document tamsulosin use in medical records and ensure patient informs ophthalmologist before any cataract or intraocular surgery. IFIS risk persists even months after stopping the drug.
- Reserve FDCs appropriately — Tamsulosin + Dutasteride combination should be considered only when prostate volume exceeds 30–40 mL with moderate-to-severe LUTS; monotherapy suffices for smaller glands.
- Ejaculatory dysfunction counselling — Discuss ejaculatory changes (retrograde ejaculation) upfront, especially with younger sexually active patients.
- Not a treatment for all LUTS — Tamsulosin is ineffective for overactive bladder, isolated nocturia, or bladder storage symptoms; confirm outlet obstruction before initiating.
- Postural precaution in elderly — Counsel patients to rise slowly from sitting or supine position, particularly in the first few weeks of therapy.
Version
RxIndia v1.0 — 03 Apr 2025
Reference
- CDSCO product insert (Urimax, Cipla)
- Indian Pharmacopoeia / NFI 2021
- NLEM 2022
- API Textbook of Medicine
- Indian Urological Association practice guidelines
- AIIMS Delhi Hospital Formulary
⚖️
Clinical Responsibility
This platform is designed strictly for healthcare professionals. Data provided is synthesized from authoritative pharmacological sources and clinical registries. Do not use for consumer medical decisions. Always verify critical dosing and contraindications with official institutional protocols and peer-reviewed journals.
Content Feedback
Is this information helpful?
Help us improve our clinical database for the medical community.